Yang, Mengling
Yao, Jingyu
Jia, Lin
Kocab, Andrew J. https://orcid.org/0000-0001-6069-2166
Zacks, David N. https://orcid.org/0000-0001-8592-5165
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Eye Institute (R01 EY020823)
U.S. Department of Health & Human Services | NIH | National Eye Institute (P30EY-07003)
U.S. Department of Health & Human Services | NIH | National Eye Institute (P30EY007003)
U.S. Department of Health & Human Services | NIH | National Eye Institute (R01 EY020823)
U.S. Department of Health & Human Services | NIH | National Eye Institute (P30EY007003)
U.S. Department of Health & Human Services | NIH | National Eye Institute (R01 EY020823)
U.S. Department of Health & Human Services | NIH | National Eye Institute (P30EY007003)
U.S. Department of Health & Human Services | NIH | National Eye Institute
ONL Therapeutics Research Fund
U.S. Department of Health & Human Services | NIH | National Eye Institute
U.S. Department of Health & Human Services | NIH | National Eye Institute
U.S. Department of Health & Human Services | NIH | National Eye Institute
U.S. Department of Health & Human Services | NIH | National Eye Institute
U.S. Department of Health & Human Services | NIH | National Eye Institute
Article History
Received: 15 April 2024
Revised: 30 July 2024
Accepted: 1 August 2024
First Online: 8 August 2024
Competing interests
: Two of the authors have relevant disclosures. AK is an employee of ONL Therapeutics, the company that makes ONL1204. DZ is an employee of the University of Michigan but is a co-founder of ONL Therapeutics with a personal financial interest in the company. Zacks also holds patents through the University of Michigan that are licensed to ONL Therapeutics.
: All animal experiments were approved by the University of Michigan Animal Care Committee and conformed to the Association for Research in Vision and Ophthalmology (ARVO) guidelines.